← Back to Clinical Trials
Recruiting NCT04579471
Prevalence and Outcome of SARS-CoV-2 Infection & COVID-19 in Transplant Recipients: The COVITRA Study
Trial Parameters
Condition Covid19
Sponsor Universitaire Ziekenhuizen KU Leuven
Study Type OBSERVATIONAL
Phase N/A
Enrollment 2,000
Sex ALL
Min Age 18 Years
Max Age 90 Years
Start Date 2020-07-01
Completion 2021-12-31
All Conditions
Interventions
SARS-CoV-2 IgG
Brief Summary
This project will provide novel data using a large cohort of more than 3000 transplanted patients. Risk and protective factors for SARS-CoV-2 infection and COVID-19 disease severity will be identified. The proportion of patients who develop antibodies after infection will be revealed. In this way the presence of these antibodies can be evaluated as a test for prior infection. Our study additionally will demonstrate how long these antibodies remain present and whether they are protective against a new infection.
Eligibility Criteria
Inclusion Criteria: * all patients who underwent solid organ or hematopoietic cell transplantation at UZ Leuven and who give informed consent Exclusion Criteria: * age under 18 years